Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Pancreatic Neoplasms 2Ovarian Neoplasms 2Breast Neoplasms 2Uterine Cervical Neoplasms 1Neoplasms 1Kidney Neoplasms 1Esophageal Neoplasms 1Carcinoma, Hepatocellular 1

Interventions

Cisplatin 160Fluorouracil 134Paclitaxel 125Radiotherapy 117Oxaliplatin 87Carboplatin 71Docetaxel 70Irinotecan 59pembrolizumab 57Capecitabine 57Leucovorin 56Radiation 47Surgical Procedures, Operative 33Drug Therapy 33Esophagectomy 31Cetuximab 25Neoadjuvant Therapy 24Nivolumab 23Bevacizumab 21Trastuzumab 20camrelizumab 19S 1 (combination) 19Chemoradiotherapy 17Albumin-Bound Paclitaxel 16Magnetic Resonance Spectroscopy 15Epirubicin 15tislelizumab 14Taxes 13Radiotherapy, Intensity-Modulated 13Cyclophosphamide 13

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Esophageal Neoplasms × Histocompatibility Testing × Clear all
NCT00319735 2016-04-28

Cetuximab and Radiation Therapy for Surgically Resectable Esophageal and Gastroesophageal (GE) Junction Carcinomas

Hoosier Cancer Research Network

Phase 2 Completed
41 enrolled 18 charts
Gastrointestinal

Esophageal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡